Phase III clinical study CheckMate -816 results released: Odivo® (Navulimab) combined with chemotherapy as a neoadjuvant treatment for patients with resectable non-small cell lung cancer can significantly improve tumor pathology and complete remission

2021 Nian 4 Yue 10 days, Bristol-Myers Squibb (NYSE: BMY ) announced CheckMate -816 data from clinical studies.

2021 Nian 4 Yue 10 days, Bristol-Myers Squibb (NYSE: BMY ) announced CheckMate -816 data from clinical studies.

CheckMate -816 is the first randomized, phase III clinical study to prove that neoadjuvant immune combination therapy can bring significant improvement to the pathological complete remission of patients with non-small cell lung cancer .

Professor Nicolas Girard , Director of the Medical Oncology Department of the Curie Institute of France, said: “ The ultimate goal of early cancer treatment is to prevent the recurrence of the disease and at the same time strive to find a cure for the patient.

Odivo combined with chemotherapy also improved in key secondary research endpoints, including primary pathological remission ( MPR ).

Three cycles of Odivo combined with chemotherapy is safe, and no new safety signals have been observed.

In addition, compared with chemotherapy alone, more patients in this study who used Odivo combined with chemotherapy as neoadjuvant treatment underwent surgery ( 83% vs 75% ), indicating that Odivo combined with chemotherapy did not reduce the cost of surgery.

Dr.

In the broader field of early-stage non-small cell lung cancer, Bristol-Myers Squibb and its partners are jointly exploring the use of immunotherapy in neoadjuvant, adjuvant or perioperative period, as well as the combination of concurrent radiotherapy and chemotherapy.

About About CheckMate -816 CheckMate -816

Checkmate-816 is a randomized, open-label, multi-center phase III clinical study, which aims to evaluate the efficacy of Odivo combined chemotherapy for neoadjuvant therapy in patients with non-small cell lung cancer, compared with chemotherapy alone.

Checkmate-816 is a randomized, open-label, multi-center phase III clinical study, which aims to evaluate the efficacy of Odivo combined chemotherapy for neoadjuvant therapy in patients with non-small cell lung cancer, compared with chemotherapy alone.

About Lung Cancer About Lung Cancer

Lung cancer is the leading cause of cancer deaths worldwide.

Lung cancer is the leading cause of cancer deaths worldwide.
Non-small cell lung cancer and small cell lung cancer are the two main types of lung cancer.
Among them, non-small cell lung cancer ( NSCLC ) is the most common, accounting for 84% of all confirmed cases .
Most NSCLC patients (about 60% ) have not yet metastasized at the time of diagnosis.
Although many patients with non-metastatic non-small cell lung cancer have undergone surgery, 30% to 55% of patients will relapse and die of the disease after surgery.
Therefore, a variety of treatment options are needed, including preoperative (neo-adjuvant therapy) and / or post-operative (adjuvant therapy) to improve the long-term survival of patients.


Leave a message here